Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00062205 · ClinicalTrials.gov registry record · Phase 2

Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor

A Phase 2 study, sponsored by City of Hope Medical Center.

Completed
Registry status
Phase 2
Development phase
40
Enrollment target

NCT00062205: Completed Phase 2 study, sponsored by City of Hope Medical Center.

NCT00062205 is a Phase 2 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 40 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00062205, a Phase 2 study, has completed, sponsored by City of Hope Medical Center.

COMPLETED
Registry status
Phase 2
Development phase
40 participants
Enrollment target

Study Summary

RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: This phase II trial is studying how well imatinib mesylate works in treating patients with recurrent Ewing's family of tumors or desmoplastic small round-cell tumor.

Interventions

  • DRUG imatinib mesylate

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2002-06
Est. Completion 2007-06
Phase Phase 2
City of Hope Medical Center

582 total trials

What the finished NCT00062205 record still lists

NCT00062205 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower).

The record links to 0 conditions, and to 1 intervention - of which imatinib mesylate is the first listed.

NCT00062205 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00062205 about?

NCT00062205 is a clinical study titled "Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor". RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: This phase II trial is studying how well imatinib mesylate works in treating patients with recurrent Ewing's family of tumors or desmoplastic small round-cell tumor.

What is the current status of trial NCT00062205?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2002-06. Estimated completion is 2007-06.

What interventions are being tested in trial NCT00062205?

The interventions under investigation include: imatinib mesylate (DRUG).

Who is sponsoring clinical trial NCT00062205?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00062205's enrollment target sits among peer trials

40 1362nd of 2000 higher than 542 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00062205, the US trial registry maintained by the National Library of Medicine. NCT00062205 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.